Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 29 March 2024, including: Merck & Co., Inc. progresses cardiovascular strategy; Novo Nordisk A/S purchase builds heart failure presence; CRL setbacks for Regeneron Pharmaceuticals, Inc.; ITF faces challenging Duchenne field; and AbbVie Inc. needs to freshen up.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy" - Scrip, 26 Mar, 2024.)
(Also see "Novo Pumps Up Heart Failure Prospects With Cardior Purchase" - Scrip, 25 Mar, 2024.)
(Also see "Regeneron Oncology Setback Delivered By US FDA Crackdown On Accelerated Approval" - Scrip, 25 Mar, 2024.)
(Also see "ITF Has A Fight On Its Hands In Duchenne" - Scrip, 25 Mar, 2024.)
(Also see "AbbVie Needs To Freshen Up" - Scrip, 22 Mar, 2024.)